financetom
Business
financetom
/
Business
/
BASF to prepare agricultural business for IPO, reports Bloomberg
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BASF to prepare agricultural business for IPO, reports Bloomberg
Sep 21, 2024 10:36 PM

FRANKFURT, Sept 18 (Reuters) - BASF plans to

prepare its agricultural chemicals business for an initial

public offering in the next few years as part of restructuring

measures set to be announced by the chemicals group this month,

Bloomberg News reported on Wednesday.

BASF's new CEO, Markus Kamieth, will announce a series of

overhaul measures at the capital markets day set for Sep. 26-27,

including plans for the future of its coatings business,

Bloomberg reported, citing people familiar with the matter.

While the agricultural chemicals business is to be prepared

for a listing, the German firm could also signal its willingness

to sell parts of the coatings business or bring in a partner.

BASF declined to comment on the report.

"We will publish information on our strategy next week at

our capital markets day," a company spokesperson told Reuters.

BASF shares rose 3.6%, the top gainer in the DAX, following

the report.

According to Bloomberg, BASF could also announce plans for

the further development of the battery materials business.

The proceeds from the sale of assets could be used to

strengthen the balance sheet, according to the report.

In December last year, BASF announced plans to turn its

agriculture, battery materials and coatings businesses into

autonomous units in a bid to try to boost earnings.

However, previous CEO Martin Brudermueller said at the time

that there was no intention to sell these businesses.

BASF's Agricultural Solutions unit had about 10 billion

euros in sales last year, competing with Bayer, Corteva ( CTVA )

and China's Syngenta.

($1 = 0.8990 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved